CNS Drugs

, Volume 16, Issue 7, pp 435–444 | Cite as

Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease

Potential for Pharmacological Intervention
  • Miia Kivipelto
  • Mikko P. Laakso
  • Jaakko Tuomilehto
  • Aulikki Nissinen
  • Hilkka Soininen
Current Opinion


This paper focuses on hypertension and hypercholesterolaemia as risk factors for Alzheimer’s disease and, as such, subjects for prevention. The long-term, prospective, population-based studies regarding the relationship between hypertension or hypercholesterolaemia and Alzheimer’s disease, and the clinical studies regarding the association between antihypertensive or lipid-lowering medications and the risk of Alzheimer’s disease, are reviewed. These studies provide evidence to suggest that elevated blood pressure and cholesterol levels earlier in life may have an important role in the development and expression of late-life Alzheimer’s disease. Based on these data, we propose that proper, early interventions aimed at reducing these cardiovascular risk factors may have an impact on the future incidence and prevalence of Alzheimer’s disease.


Dementia Simvastatin Amyloid Precursor Protein Vascular Dementia Calcium Channel Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are grateful for grants from the Academy of Finland (37573 and 63645) and the EVO (477268 and 5510) and have no conflicts of interest that are relevant to the contents of this article.


  1. 1.
    Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337–42PubMedCrossRefGoogle Scholar
  2. 2.
    Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153–60PubMedCrossRefGoogle Scholar
  3. 3.
    Viitanen M, Guo Z. Are cognitive function and blood pressure related? Drugs Aging 1997; 11: 165–9PubMedCrossRefGoogle Scholar
  4. 4.
    Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5PubMedCrossRefGoogle Scholar
  5. 5.
    Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer’s disease. Neuroepidemiology 1998; 17: 14–20PubMedCrossRefGoogle Scholar
  6. 6.
    Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49–55PubMedCrossRefGoogle Scholar
  7. 7.
    Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population-based study. BMJ 2001; 322: 1447–51PubMedCrossRefGoogle Scholar
  8. 8.
    Morris MC, Scherr PA, Hebert LE, et al. Association of incident Alzheimer’s disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640–6PubMedCrossRefGoogle Scholar
  9. 9.
    Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60PubMedCrossRefGoogle Scholar
  10. 10.
    Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer’s diseases independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 1997; 315: 1045–9PubMedCrossRefGoogle Scholar
  11. 11.
    Romas SN, Tang M-X, Berglund L, et al. ApoE genotype, plasma lipids, lipoproteins, and Alzheimer’s disease in community elderly. Neurology 1999; 53: 517–21PubMedCrossRefGoogle Scholar
  12. 12.
    Slooter AJC, Ruitenberg A, van Duijn CM, et al. The effect of apoE on dementia is not through atherosclerois: the Rotterdam Study. Neurology 2000; 54: 2357–8Google Scholar
  13. 13.
    Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 1995; 45: 1092–6PubMedCrossRefGoogle Scholar
  14. 14.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255–64CrossRefGoogle Scholar
  15. 15.
    Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s treatment trial of hypertension in older adults. BMJ 1996; 312: 801–5PubMedCrossRefGoogle Scholar
  16. 16.
    Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51PubMedCrossRefGoogle Scholar
  17. 17.
    Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–6PubMedCrossRefGoogle Scholar
  18. 18.
    in’t Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22: 407–12PubMedCrossRefGoogle Scholar
  19. 19.
    Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–43PubMedCrossRefGoogle Scholar
  20. 20.
    Wolozin B. Statin-Alzheimer disease association not yet proven [letter]. Arch Neurol 2000; 58: 1023Google Scholar
  21. 21.
    Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627–31PubMedCrossRefGoogle Scholar
  22. 22.
    Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223–7PubMedCrossRefGoogle Scholar
  23. 23.
    Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the “rule of halves” still valid? J Hum Hypertens 1997; 11: 213–20PubMedCrossRefGoogle Scholar
  24. 24.
    Kastarinen MJ, Salomaa VV, Vartiainen EA, et al. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998; 16: 1379–87PubMedCrossRefGoogle Scholar
  25. 25.
    Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16 Suppl. 1: S45–51Google Scholar
  26. 26.
    Wyss JM, van Groen T. Neurologic consequences of hypertension and antihypertensive drug therapy. Curr Opin Nephrol Hypertens 1994; 3: 228–35PubMedCrossRefGoogle Scholar
  27. 27.
    Braak E, Griffing K, Arai K, et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl.3: 14–22PubMedCrossRefGoogle Scholar
  28. 28.
    Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426–32PubMedCrossRefGoogle Scholar
  29. 29.
    Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108: 538–47PubMedCrossRefGoogle Scholar
  30. 30.
    Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. Clin Pharm 1994; 34: 989–96Google Scholar
  31. 31.
    Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231–6PubMedCrossRefGoogle Scholar
  32. 32.
    Gengo F, Cwudzinski D, Kinkel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995; 18: 209–14PubMedCrossRefGoogle Scholar
  33. 33.
    Santanello NC, Barber BL, Applegate WB, et al. Effects of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J Am Geriatr Soc 1997; 45: 8–14PubMedGoogle Scholar
  34. 34.
    Beffert U, Danik M, Krzywkowski P, et al. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer’s disease. Brain Res Rev 1998; 27: 119–42PubMedCrossRefGoogle Scholar
  35. 35.
    Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer’s disease: is there a link? Neurology 2001; 57: 1089–93PubMedCrossRefGoogle Scholar
  36. 36.
    Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: 106–14CrossRefGoogle Scholar
  37. 37.
    Pasquier F, Leys D, Scheltens P. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer’s disease. J Neural Transm Suppl 1998; 54: 117–27Google Scholar
  38. 38.
    Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer’s disease: the Nun Study. JAMA 1997; 277: 813–7PubMedCrossRefGoogle Scholar
  39. 39.
    Sparks DL, Scheff S, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162–9PubMedCrossRefGoogle Scholar
  40. 40.
    Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging 2000; 21: 57–62PubMedGoogle Scholar
  41. 41.
    Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512–21PubMedCrossRefGoogle Scholar
  42. 42.
    Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 5856–61PubMedCrossRefGoogle Scholar
  43. 43.
    Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase Alzheimer’s disease AM 10. Proc Natl Acad Sci U S A 2001; 98: 5815–20PubMedCrossRefGoogle Scholar
  44. 44.
    Haley RW. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000; 57: 1410–2Google Scholar
  45. 45.
    Wolozin B. A fluid connection: cholesterol and Aβ. Proc Natl Acad Sci U S A 2001; 98: 5371–3PubMedCrossRefGoogle Scholar
  46. 46.
    Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998; 95: 6460–4PubMedCrossRefGoogle Scholar
  47. 47.
    Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2001; 8: 890–9PubMedCrossRefGoogle Scholar
  48. 48.
    Hartmann T. Cholesterol, Aβ and Alzheimer’s disease. Trends Neurosci 2001; 24(11 Suppl.): S45–8PubMedCrossRefGoogle Scholar
  49. 49.
    Sarti C, Kaarisalo M, Tuomilehto J. The relationship between cholesterol and stroke. Drugs Aging 2000; 17: 33–51PubMedCrossRefGoogle Scholar
  50. 50.
    Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001; 187:81–9PubMedCrossRefGoogle Scholar
  51. 51.
    Locatelli S, Lütjohann D, Schmidt HH-J, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002; 59: 213–9PubMedCrossRefGoogle Scholar
  52. 52.
    Joseph J, Shukitt-Hale B, Denisova NA, et al. Copernicus revisited: amyloid beta in Alzheimer’s disease. Neurobiol Aging 2001; 22: 131–46PubMedCrossRefGoogle Scholar
  53. 53.
    Kalaria RN, Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: S115–23PubMedCrossRefGoogle Scholar
  54. 54.
    Di Iorio A, Lupinetti M, Abate G. Are vascular factors involved in Alzheimer’s disease? Facts and theories. Aging Clin Exp Res 1999; 11: 345–52Google Scholar
  55. 55.
    Aguero-Torres H, Winblad B. Alzheimer’s disease and vascular dementia: some points of confluence. Ann N Y Acad Sci 2000; 903: 547–52PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Miia Kivipelto
    • 1
  • Mikko P. Laakso
    • 1
  • Jaakko Tuomilehto
    • 2
  • Aulikki Nissinen
    • 2
  • Hilkka Soininen
    • 1
    • 3
  1. 1.Department of Neuroscience and NeurologyUniversity of KuopioKuopioFinland
  2. 2.National Public Health InstituteHelsinkiFinland
  3. 3.Department of NeurologyKuopio University HospitalKuopioFinland

Personalised recommendations